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Abstract
The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the
treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of
new-onset diabetes mellitus and a review of the literature suggesting an adverse event association. In the first patient with
HIV, we postulate that ledipasvir/sofosbuvir increased the levels of tenofovir and thereby potentiated hyperglycemia. In the
second case of a patient with prediabetes, ledipasvir/sofosbuvir appeared to increase insulin resistance. A literature review
further supported an association of hyperglycemia and the use of ledipasvir/sofosbuvir. Hence, clinicians should be cautious
about worsening of glucose intolerance, and more studies are warranted to explore the underlying mechanism.
Keywords
new-onset diabetes mellitus, ledipasvir/sofosbuvir, chronic hepatitis C, glucose intolerance
Received 22 September 2015. Accepted for publication 11 November 2015

Introduction
The combination therapy of ledipasvir/sofosbuvir (ie,
Harvoni) was approved by the Food and Drug Administration
in 2014 for eradication of chronic genotype 1 hepatitis C
virus (HCV) infections. Clinical trial data have demonstrated
this combination to be well tolerated. An adverse glycemic
event, as described herein, either independently or in combination is not mentioned with the current drug product information. In this case report, we present 2 patients who had
new-onset diabetes mellitus related to the combination therapy of ledipasvir/sofosbuvir.

Case Report
Case 1
A 58-year-old nonobese (body mass index [BMI] 24 kg/m2)
African American male with history of chronic HCV (genotype 1b) and HIV presented to the emergency room with polyuria, polydipsia, and fatigue for 2 weeks duration. Laboratory
analysis indicated elevated plasma glucose of 764 mg/dL with
an anion gap of 12. He did not have known diabetes mellitus in
the past and there was no family history of diabetes. History
was significant for recent addition of ledipasvir/sofosbuvir 4
weeks prior to presentation. He was also on tenofovir as a part
of highly active antiretroviral therapy. Hemoglobin A1c 1
month before starting ledipasvir/sofosbuvir was 5.5% and

currently increased to 10.5%. There was no other ascertainable
etiology for sudden new-onset hyperglycemia including use of
glucocorticoids, diuretics, statins, atypical antipsychotics, or
quinolones. No focus of infection could be identified and serum
lipase was normal at 31 U/L. A potential drug-drug interaction
between ledipasvir/sofosbuvir and tenofovir was suspected.
Hence, the antiretroviral regimen was changed from emtricitabine/rilpivirine/tenofovir (Complera) and raltegravir to rilpivirine/zidovudine and raltegravir. He was continued on
ledipasvir/sofosbuvir for a total duration of 12 weeks. Over the
next several months, the insulin dose had to be titrated down
and eventually stopped due to several bouts of hypoglycemia.
Hemoglobin A1c dropped to 6.0% within the next 3 months. At
present, the patient is on diet control alone.

Case 2
The second patient is a 55-year-old obese (BMI 38 kg/m2)
African American male with chronic HCV (genotype 1b)
who presented to the emergency room with polyuria and
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polydipsia. Plasma glucose was 548 mg/dL with an anion
gap of 14. He was started on ledipasvir/sofosbuvir 8 weeks
prior to presentation at which time random serum glucose
levels had ranged from 70 to 140 mg/dL. Hemoglobin A1c
was 6.3% before starting ledipasvir/sofosbuvir and more
than 14% on presentation. He was only on diet control and
exercise for the management of prediabetes. Similar to the
first patient, there was no other clear etiology for the hyperglycemia including history of exposure to glucocorticoids,
diuretics, statins, atypical antipsychotics, or quinolones. No
ongoing infection was identified and there was no evidence
of pancreatitis. He was initially managed with parenteral
insulin and was subsequently changed to basal insulin and
metformin. Random glucose levels 1 month after discharge
ranged from 80 to 140 mg/dL. Over the next 3 months after
initiation of hyperglycemia treatment, his BMI improved to
35 kg/m2.

Discussion
The combination use of ledipasvir/sofosbuvir is becoming a
very effective treatment modality for HCV with hitherto
minor side effects. Ledipasvir is a potent inhibitor of HCV
nonstructural protein 5A (NS5A), a viral phosphoprotein that
plays an important role in viral replication, assembly, and
secretion. Sofosbuvir is an inhibitor of HCV nonstructural
protein 5B (NS5B), also a viral phosphoprotein, which leads
to cessation of HCV viral RNA replication in all HCV genotypes.1 Although hyperglycemia is not a well-known adverse
reaction with ledipasvir/sofosbuvir, these 2 cases of sudden
new-onset diabetes suggest plausible mechanisms since no
other secondary causes of hyperglycemia were identified.
Thus, ledipasvir can increase the serum concentration of
tenofovir and thereby potentiate one of its known adverse
effects, hyperglycemia, as suggested in the first case substantiated with removal of tenofovir.2 The serum concentration
of tenofovir can increase in the presence of agents such as
ritonavir and cobicistat, and concurrent administration is not
recommended as per the drug product information of ledipasvir/sofosbuvir. The second patient was obese and had prediabetes on diet control alone at the time of initiation of
ledipasvir/sofosbuvir. The hyperglycemia improved significantly after starting metformin and basal insulin. A possible
mechanism in this case could be drug-induced triggering of
aggravated insulin resistance in view of the salutary weight
and metabolic response to metformin treatment.3
In support of our findings, a review of the supplementary
data in the original phase 3 trial (ie, the ION-3 clinical trial)4
showed that in those who received ledipasvir/sofosbuvir for
12 weeks, the hyperglycemia rates (using grades defined by to
the Common Terminology Criteria for Adverse Events, hyperglycemia, grade 1: serum glucose > upper limit of normal—160
mg/dL; grade 2: >160-250 mg/dL; grade 3: >250-500 mg/dL:

and grade 4: >500 mg/dL)5 were 33.3% (grade 1), 11.6%
(grade 2), and 2.3% (grade 3). Those who received the medication for 8 weeks had hyperglycemia at the following rates:
21.4% (grade 1), 7.9% (grade 2), and 1.4% (grade 3). Of
note, these adverse glycemic changes were not emphasized
in the study’s main findings in contrast to adverse effects
such as hyperbilirubinemia and anemia albeit with rates
similar.
As with prior treatment modalities for hepatitis C,6 these
2 cases raise concern regarding adverse effects related to
ledipasvir/sofosbuvir. Currently, there are no guidelines on
monitoring of hyperglycemia in patients using ledipasvir/
sofosbuvir. However, in view of these cases, we suggest clinicians to be vigilant in patients with high-risk features such
as obesity, glucose intolerance, and/or strong family history
of diabetes. We also recommend observing caution when
using ledipasvir/sofosbuvir concurrently with drugs that
already increase the risk of dysglycemia.7 Monitoring of glucose or hemoglobin A1c before and during treatment could
be considered in the aforementioned circumstances.
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